Company intelligence / Profile preview
NodThera
Chesterford Research Park/Saffron Walden*, Essex, United Kingdomnodthera.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
NodThera has advanced a portfolio of brain‐penetrant, highly selective NLRP3 inflammasome inhibitors into clinical trials. The company reports a wealth of pre-clinical and clinical data supporting its approach to treating chronic inflammatory conditions. It was recognized as a 'Fierce 15' company by Fierce Biotech in August 2024 for its leadership in this space.
- Therapeutic areas
- NeurologyImmunologyCardiovascularEndocrinology
- Modalities
- Small molecules (NLRP3 inflammasome inhibitors)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on NodThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NodThera.